Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,126.06
(
0.00%
)
US TECH 100
25,862.34
(
-0.35%
)
Dow Jones
49,447.43
(
0.00%
)
Brent Oil
91.53
(
-1.22%
)
Bitcoin
75,299.99
(
1.95%
)
News Focus
News Focus
Post# of 257426
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122876
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 244766

Monday, 07/29/2024 1:27:49 PM

Monday, July 29, 2024 1:27:49 PM

Post# of 257426
GH—FDA approves blood-based CRC diagnostic:

https://finance.yahoo.com/news/guardant-health-shield-blood-test-103000648.html

I’ve previously opined (#msg-173463096) that a blood test for colorectal cancer can’t match the sensitivity/specificity of a stool-based test such as EXAS’ Cologuard, particularly for precancerous lesions. However, the blood test is plainly more convenient.

In today's trading, GH is +3% and EXAS is -2%.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today